# [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

> **NCT06125028** · PHASE3 · TERMINATED · sponsor: **Pentixapharm AG** · enrollment: 8 (actual)

## Conditions studied

- Marginal Zone Lymphoma

## Interventions

- **DRUG:** [68Ga]Ga-PentixaFor
- **DRUG:** [18F]Fluorodeoxyglucose

## Key facts

- **NCT ID:** NCT06125028
- **Lead sponsor:** Pentixapharm AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-05-20
- **Primary completion:** 2025-07-18
- **Final completion:** 2025-07-18
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** low recruitment rate
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06125028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06125028, "[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06125028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*